Plozasiran for Severe Hypertriglyceridemia

Name: Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC
Uploaded: 2026-09-02T04:00:00+00:00
Duration: 3 min 15 s
Description: From ESC 2026 in Munich, Dr. Gerald Watts explores the 12-month findings from the phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in patients with sever

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Cardiology
APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Erik Stroes
Erik Stroes
ACACIA-HCM: What Do the Phase 3 Results Show?
ACACIA-HCM: What Do the Phase 3 Results Show?
Cardiology Conferences
ACACIA-HCM: What Do the Phase 3 Results Show?
Ahmad Masri, MD, MS
Ahmad Masri, MD, MS
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
CME/CE
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Brendon Neuen, MBBS, PhD; Katherine Tuttle, MD
0.25 credits
Brendon Neuen, MBBS, PhD; Katherine Tuttle, MD
0.25 credits
HCM vs HFpEF: Avoiding Common Diagnostic Pitfalls
HCM vs HFpEF: Avoiding Common Diagnostic Pitfalls
Cardiology
HCM vs HFpEF: Avoiding Common Diagnostic Pitfalls
Ahmad Masri, MD, MS
Ahmad Masri, MD, MS

Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC

Recommended

Title